Clinical trial
A Phase II Study of Neoadjuvant Toripalimab Plus Platinum-based Doublet for Potentially Resectable Stage III Non-small Cell Lung Cancer
NCT04304248 is registered in ClinicalTrials.gov with Hao Long as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Neoadjuvant Toripalimab Plus Platinum-based Doublet for Potentially Resectable Stage III Non-small Cell Lung Cancer
- Lead sponsor
- Hao Long
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 1, 2019
- Completion date
- July 30, 2026
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non small cell lung cancer